| Outcomes |
| Q1. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Severe toxicity |
| • Morphologic CR (or CR) |
| • Allogeneic hematopoietic cell transplantation |
| • Hospitalization (non–intensive care unit) |
| • Burdens on caregivers |
| Q2. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Recurrence or duration of response |
| • Morphologic CR (or CR) |
| • Allogeneic hematopoietic cell transplantation |
| • Severe toxicity |
| • Burdens on caregivers |
| Q3. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Recurrence or duration of response |
| • Severe toxicity |
| • Hospitalization (non–intensive care unit) |
| Q4. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Recurrence or duration of response |
| • Morphologic CR (or CR) |
| • Severe toxicity |
| • Burdens on caregivers |
| Q5. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Severe toxicity |
| • Burdens on caregivers |
| Q6. |
| • Mortality/survival |
| • Functional-status impairment |
| • Burden on caregivers |
| • Hospice care |
| • Major bleeding |
| • Platelet transfusion refractoriness |
| Outcomes |
| Q1. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Severe toxicity |
| • Morphologic CR (or CR) |
| • Allogeneic hematopoietic cell transplantation |
| • Hospitalization (non–intensive care unit) |
| • Burdens on caregivers |
| Q2. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Recurrence or duration of response |
| • Morphologic CR (or CR) |
| • Allogeneic hematopoietic cell transplantation |
| • Severe toxicity |
| • Burdens on caregivers |
| Q3. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Recurrence or duration of response |
| • Severe toxicity |
| • Hospitalization (non–intensive care unit) |
| Q4. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Recurrence or duration of response |
| • Morphologic CR (or CR) |
| • Severe toxicity |
| • Burdens on caregivers |
| Q5. |
| • Mortality/survival |
| • Quality-of-life impairment |
| • Functional-status impairment |
| • Severe toxicity |
| • Burdens on caregivers |
| Q6. |
| • Mortality/survival |
| • Functional-status impairment |
| • Burden on caregivers |
| • Hospice care |
| • Major bleeding |
| • Platelet transfusion refractoriness |